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2016 Comprehensive Update of the Banff Working Group on Liver 
Allograft Pathology:  
Introduction of Antibody-mediated Rejection by The Banff 
Working Group 
 
Abbreviations: ADCC: antibody-dependent cellular cytotoxicity; AIH: autoimmune 
hepatitis; AMR: antibody-mediated rejection; C4d: complement component 4d; CDC: 
complement-dependent cytotoxicyt; DSA: donor-specific antibodies; FFPE: formalin- fixed 
paraffin-embedded; HCV: hepatitis C virus; HLA: human leukocyte antigen; MFI: mean 
fluorescent intensity; OLTx: orthotopic liver transplantation; TCMR: T cell- mediated 
rejection; 
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INTRODUCTION 
 
The Banff Foundation and other professional societies endorse international consensus documents containing 
recommendations and criteria for solid organ allograft rejection, including kidney(1, 2), heart(3, 4), liver(5-7), lung(4), 
and pancreas(8). Kidney, heart, and pancreas consensus systems currently recognize two distinct, but sometimes 
overlapping forms of allograft rejection that are based primarily on immunological mechanisms of graft injury:  1) “T 
cell-mediated (TCMR)”; and 2) “antibody-mediated rejection (AMR)”.  TCMR terminology is preferred over older 
terms, such as “cellular” rejection; AMR terminology is preferred over older terms such as “humoral” rejection. 
TCMR and AMR can occur in relative isolation or often in combination, especially in liver allografts. 
TCMR manifests consistently across all organs as allograft infiltration by admixture of inflammatory cells, 
consisting primarily of CD4+/CD3+ and CD8+/CD3+ T cells accompanied by variable numbers of CD20+ B cells, 
monocytes/macrophages, NK cells, eosinophils, plasma cells, neutrophils and mast cells (9). TCMR rejection severity 
grading is based on: a) the intensity and distribution of inflammation and tissue damage; and b) on direct or indirect 
signs of vascular injury, such as lymphocytic arteritis, which can also be seen in AMR, confluent necrosis, and/or 
microvascular disruption and non-procedural interstitial hemorrhage.  Further qualifying descriptors of TCMR include 
terms such as “acute” or “active” and “chronic” or “late”, based on the timing of the episode after transplantation, 
which likely reflect mechanism of antigen presentation. 
Early (<6 month) or acute TCMR is likely attributable to direct, while late or chronic likely depends more on indirect 
allo-antigen presentation. For example, in liver allografts, there are well-described and recognized differences in the 
appearance(-s) of TCMR early (<6 month) and late (>6 months) after transplantation, emphasized in previous Banff liver 
allograft documents(5, 10).  “Early (< 6 months)” TCMR shows a greater tendency for prevalent inflammatory bile 
duct damage, a pleomorphic inflammation composition (lymphocytes, macrophages, eosinophils, neutrophils, and 
plasma cells), and paucity of necro-inflammatory-type interface activity compared to “late” TCMR(5, 10). 
Late TCMR (>6 months), in contrast, usually shows less prevalent inflammatory bile duct damage, more 
homogeneous inflammatory infiltrate composition (lymphocytes, macrophages, and plasma cells), and a greater 
tendency for low-grade interface and perivenular necro-inflammatory-type activity(5, 10).  As originally 
predicted(11), many cases of idiopathic post-transplant hepatitis would probably now be categorized as late onset T 
cell and/or chronic AMR (see below) in DSA+ patients.  Therefore, “idiopathic post-transplant hepatitis”, as a 
specific diagnostic entity, should decrease over time as more causes of the inflammation are discovered.  However, 
occasional cases likely will still occur in DSA-negative patients. Early and late TCMR, however, are not strictly time- 
delineated and considerable overlap exists so strict separation between the two can be problematic (5, 10). 
Acute AMR also manifests fairly consistently across kidney, heart, and pancreas allografts as serological evidence of 
allograft injury and/or dysfunction specific to each organ and microvascular endothelial cell hypertrophy, capillary 
dilatation and rarefaction(12, 13), and so-called “capillaritis” or “microvasculitis”.   Capillaritis is recognized as intra-
luminal pooling and/or margination of various leukocyte subsets (monocytes, macrophages, lymphocytes, neutrophils, 
and eosinophils) in dilated and irregularly-shaped capillaries(14-19).   Liver allografts, however, exhibit a widely- 
recognized, well-documented, and accepted resistance to AMR (reviewed in (20-22)), discussed below.  
Consequently, a comparatively low incidence of acute liver allograft AMR has resulted in suboptimal recognition. 
Opportunities exist, however, to understand how the liver differs from other organs and to incorporate diagnostic 
approaches that have proved successful in other organs(1-4, 19). 
The primary goals of this manuscript, therefore, are to: a) update terminology for liver allograft rejection; b) 
provide recommendations for tissue C4d staining and interpretation; c) introduce concepts and standardized criteria for 
recognition of AMR; d) provide other updates and suggestions for future investigations. 
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TERMINOLOGY UPDATES 
 
Replacement of older with newer terminology for various categories of rejection is encouraged: 
 
Older (discouraged) Terminology Newer (preferred) Terminology  
Humoral rejection Antibody-mediated rejection (AMR)  
(Acute) cellular rejection T cell-mediated rejection (TCMR)  
De novo auto-immune hepatitis Plasma cell rich-rejection 
Plasma cell hepatitis 
 
 
 
Typical T cell-Mediated Rejection (TCMR), Chronic Rejection, and Fibrosis Staging Favorable studies of 
accuracy, reproducibility, and prognostic significance of Banff classification  have  resulted  in  widespread  
adoption  and,  therefore,  enabled  an international comparison of rejection incidence and severity (23-27). But as 
emphasized in previous Banff Liver Consensus documents (5, 6, 10, 24), TCMR alone, usually responds 
favorably to increased immunosuppression and rarely leads to liver allograft failure (23-27). Little impetus exists, 
therefore, to alter the approach or criteria for typical TCMR (Tables 1 and 2). The overall incidence of TCMR after 
liver transplantation varies from 20-60%(28-30).   Typical or classical ductopenic chronic rejection is currently 
uncommon and pressing needs to update criteria are similarly not needed at this time. 
 
It has become apparent, however, that patterns of fibrosis not typically seen in association with chronic viral 
and autoimmune hepatitis commonly occur in pediatric and adult liver allografts.  These can occur with or without 
preceding TCMR episodes and some patterns might represent a manifestation of chronic antibody-mediated injury 
or mixed TCMR and chronic AMR(31-34).  We recommend, therefore, to stage fibrosis in three  distinct  
compartments,  as  suggested  by  Venturi  et  al(35)  for  pediatric  liver allografts(35): 1) portal/periportal; 2) 
sinusoidal; and 3) peri-central or perivenular (Table 2).   The findings are scored semi-quantitatively on a scale of 0 
(none) to 3 (diffuse/bridging). 
 
Atypical Presentations: Plasma Cell-Rich Rejection:  “Plasma cell hepatitis” also known as “de novo autoimmune 
hepatitis”, is a poorly understood and uncommon (~3-5% of recipients) cause of usually late (often >1 year) graft 
dysfunction that resembles native liver AIH and often arises in HCV+ recipients treated with interferon (36-41).  A number 
of observations suggest that this entity likely represents a variant of TCMR or mixed TCMR/AMR overlapping with 
autoimmunity (36, 37, 40-44).      Therefore, we are recommending the term “plasma cell-rich rejection” be applied to 
those cases in patients without AIH as an original disease.  Evidence supporting a contribution of alloimmunity includes: 
1) more prevalent and severe bile duct damage than seen in typical autoimmune hepatitis (AIH)(37); 2) an over-
representation of IgG4+ plasma cells not present in otherwise typical AIH(37) (>50% in allografts in one study(37), but ~3% 
in native liver AIH(45)); 3) more aggressive plasma cell-rich central perivenulitis than seen in typical AIH(36, 37, 46-48); 
4) DSA (esp. anti-DQ) production in ~60%(44); 5) portal microvascular C4d deposition in nearly all affected patients in 
two studies (49, 50); 6) mismatching for atypical liver/kidney microsomal autoantibodies directed against the cytosolic 
enzyme glutathione-S-transferase T1 (GSST1) in null GSTT1 genotype recipients of GSTT1+ donor livers(47, 50, 51); 
7) precipitation by γ-interferon treatment; 8) risk factors of TCMR and steroid-dependence(39, 52); and 9) possible 
antibody-dependent effector mechanism (53-55); and 10) features of TCMR or chronic rejection have been reported to 
occur in 18-24% cases(39, 48). 
 
Evidence supporting a contribution of autoimmunity includes histopathological similarities to native liver AIH 
and detection of a variety of classical(38, 39) and other autoantibodies, such as cytokeratin 8/18 auto-antibodies(56) and 
atypical liver-kidney microsomal (LKM) antibodies directed at isoforms of carbonic anhydrase III, subunit β1 of 
proteasome, and members of different glutathione S-transferase (GST) families(57), and angiotensin II Type-1 receptor 
antibodies combined with HLA DSA (58). 
Criteria for the histopathological diagnosis of plasma cell-rich rejection are shown in Table 3.  C4d stains are 
recommended on all biopsies diagnosed as plasma cell-rich rejection; IgG and IgG4 stains might also be considered to 
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better understand the underlying pathophysiology in some recipients (37). More work is needed to distinguish recurrent 
AIH from plasma cell-rich rejection. 
The  approach  and  response  to  treatment  has  been  recently  reviewed(59): corticosteroids alone or in combination 
with Azathioprine, similar to native liver AIH treatment, constitute the essential therapy(59), but high doses of steroids 
are often required and when tapered the biopsy findings might recur. 
 
 
 
INCORPORATION OF ANTIBODY-MEDIATED REJECTION (AMR) INTO THE BANFF 
SCHEMA 
General Considerations 
 
Factors influencing relative susceptibility and resistance mechanisms: Susceptibility to AMR for any vascularized 
allograft is dependent on antibody class, titer, specificity and timing, as well as density and distribution of target antigen 
expression(20). AMR has been recognized in clinical liver transplantation practice for nearly 3 decades: first with 
ABO-incompatible allografts (60-64) and later with lymphocytotoxic antibodies or DSA (65-69). Inclusion of ABO-
incompatible AMR in the Banff Schema is overdue, but inclusion of ABO-compatible AMR has been delayed because 
of widespread recognition that human liver allografts: a) were less sensitive than kidney allografts to acute adverse 
consequences of pre-formed DSA(70); and b) could protect subsequent kidney and heart allografts from the same donor 
from AMR in most, but not all, sensitized experimental animals(71, 72) and humans(73, 74). 
Indeed, Olausson et al(75) reported successful subsequent kidney transplants in 5/7 broadly sensitized (as determined 
by cell-based assays) recipients when simultaneously underwent partial auxiliary liver allografts from the same 
donors for the purpose of protecting the liver.  Two of seven, however, appeared to have experienced renal allograft 
AMR, perhaps related to class II DSA. Acute kidney allograft AMR was not seen in all sensitized recipients of 
combined liver-kidney allografts, but lower patient and kidney graft survival (~40%) did not seem to influence the 
practice of simultaneous liver- kidney in sensitized recipients. 
A variety of liver allograft AMR-resistance mechanisms all likely contribute (reviewed in (20, 21, 76)):  
1) Kupffer cells clearance of DSA, activated complement, platelet aggregates(77), and immune complexes 
formed between soluble donor class I HLA antigens and anti-class I DSA(71, 72, 78-80).  Supporting evidence 
includes:  
a) increased AMR susceptibility and decreased protection of sequentially- placed extra-hepatic allografts in 
recipients of Kupffer cell-depleted liver allografts(71, 72, 78-80); and  
b) amelioration of acute heart allograft AMR in sensitized recipients by transfection of donor class I 
genes that produce soluble HLA antigens, mimicking the effect of simultaneous liver allografts(81).  
2) Variable hepatic (reviewed in (82)) versus strong  and  constitutive  kidney(83)  and  heart(84)  
microvascular  class  II  expression provide less class II DSA targets, which might explain the preferential clearance of 
class I versus class II DSA after transplantation(85, 86).   
3) Large liver size dilutes antibody- binding across a larger endothelial cell surface; potentially explaining 
increased AMR susceptibility in reduced-size allografts(80). 
4) Liver sinusoidal endothelial cells and Kupffer cells express Fc receptors(87, 88), lack a typical 
basement membrane, and normally lined by Kupffer cells that can play protective roles (described above); all of 
these  factors  potentially  influence  antibody-endothelial  interactions.  
5)  The  liver’s regenerative capacity and ability to heal either without fibrosis or reverse fibrosis(89).  
 
Target antigen expression:  ABH blood group antigens are ubiquitously expressed on all hepatic endothelial 
cells (reviewed in (82)). HLA class I and II antigen expression has been studied in formalin-fixed, paraffin-embedded 
and frozen “normal” human livers (e.g. organ donors, biopsies obtained from patients with non-hepatic diseases, un-
involved liver resected for tumors)  using immunostaining (90-102):  all studies reported diffuse and strong class I 
HLA expression on all cell types, except hepatocytes where class I HLA expression is weaker.  HLA class II 
expression is strongest on portal, perivenular, and subcapsular dendritic cells, and Kupffer cells with DQ demonstrating 
the weakest expression. Portal vein branch endothelia class II expression was consistently negative, but portal capillary, 
sinusoidal and central vein endothelia varies from negative to focally positive(90-102).   Few studies, however, 
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specifically addressed class II expression in portal capillary/peribiliary plexus, lymphatic capillaries, inlet venules, 
and the peribiliary plexus of large extra-hepatic bile ducts.  Therefore, more work is needed on this topic. Co-existent 
disorders, such as recurrent HCV and TCMR, can upregulate allograft microvascular and other cell HLA II and thereby 
increase DSA target antigen density and accentuate the underlying pathology, discussed below(21, 22, 103). 
 
ACUTE ANTIBODY-MEDIATED INJURY 
Antibody Characteristics:    
By definition, IgM and IgG isoagglutinins are naturally encountered when blood group barriers are crossed 
and antibody titer and complement- fixing ability influence pathogenic potential(60, 104-106).  Liver allograft injury 
is more often encountered when recipients develop isoagglutinin dilutions > 1:64 after transplantation, which almost 
invariably manifest graft dysfunction and significant histopathology damage(105, 106).      Reduction to titers < 1:16 
by plasmapheresis/exchange has been targeted to largely avoid ABO-I AMR(104). Cell-based donor-specific antibody 
(DSA) detection assays show 8 – 15% recipients are DSA positive (>30 - 50% lysis)(65, 107, 108); current solid phase 
assays validated and extended these findings(22). Pre-transplant CDC+-causing antibodies are encountered in ~10 - 
15% of recipients with a female and autoimmune predilection(109-113). Assays linking the two eras show the ~96% 
of cell-based CDC-negative recipients also lacked DSA; however, >50% of isolated class I or II DSA+ patients were 
CDC- negative(86). 
Pre-transplant DSA-positivity with clinical significance in potential liver allograft recipients has been 
tentatively defined as MFI ≥ 5000.  However, the cut-off for positivity varies by laboratory and more study and 
standardization are needed.  MFI, however, is not equivalent to traditional metrics of antibody prevalence or avidity.  
Empirically, high MFI for individual or aggregated anti-HLA DSA are a useful indicator of clinically significant DSA, 
but without additional testing (e.g. titration studies, C1q assay), an isolated MFI value can be misleading(114): low 
MFI might represent a high titer complement-binding DSA (prozone effect). 
Regardless, the vast majority of lower MFI class I DSA (<10,000 MFI) resolves shortly after transplantation, but C4d 
deposits can be detected in some highly sensitized recipients early after orthotopic liver transplantation (OLTx) without 
apparent short-term, but of unknown long term consequences (109, 113).  Clearly, however, preformed DSA does not 
adversely influence short-term survival in the vast majority of low to moderately (< 8,000 MFI) sensitized recipients 
(109-113, 115).  High-MFI class II DSA (≥10,000), however, persist in ~1/3 of recipients (109) associated with an 
increased risk of early TCMR, and perhaps, mixed TCMR and acute AMR(109).  A tiny fraction (<5%) of highly 
sensitized (DSA+) recipients have sufficient DSA (usually multiple class I and II usually in high MFI/titers) to cause 
clinically significant acute AMR(112, 115, 116). 
The most dramatic and clinically significant acute AMR usually occurs within the first several weeks after 
transplantation in highly sensitized recipients(67, 107), who usually harbor polyspecific high titer/high MFI antibodies; 
many also fix complement, but non-completing fixing antibodies cannot be always considered to be benign.  Rapid 
allograft failure caused by frank acute AMR: microvascular injury, thrombosis, and hemorrhagic necrosis(117) can 
rarely occur, but a less fulminant acute AMR presentation is more commonly seen, characterized by graft 
dysfunction/hyperbilirubinemia(107, 108, 
115, 118), thrombocytopenia(107, 108, 115, 118), low serum complement levels(107,108), DSA persistence after 
transplant (more common with class II), appearance of circulating immune complexes(20, 107, 108), and 
histopathological changes discussed below. The degree of post-transplant transaminasemia is generally out of 
proportion to the donor liver quality and often the downward trend of transaminasemia is blunted. 
 
Lower-level sensitization usually results in rapid DSA disappearance and either no injury or transient antibody-
mediated damage often misrepresented as “preservation injury” (20, 107, 108). 
The rapid DSA clearance accounts for protection of sequentially-placed allografts from the same donor(73, 
119). Recent studies, however, show this “protection” is occasionally only partial and the kidney can experience AMR:   
this occurs more commonly with class II than class I DSA, which rarely causes problems (85, 109, 120). Perhaps less 
efficient class II DSA clearing is attributable to lower density class II expression in the liver. Acute AMR can also occur 
later (>6 months) after transplantation(121) associated with the appearance of de novo DSA, discussed in greater detail, 
below. 
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Acute AMR Histopathology 
Acute AMR is recognized in all solid organ allograft primarily by capillary and other micro-vessel pathology. 
Linear and occasionally granular microvascular (portal vein and capillary, inlet venule, and focal sinusoidal and central 
vein) endothelial cell C4d deposition is usually present and required under current criteria.    Routine histopathological 
changes in non-hepatic allografts include endothelial cell hypertrophy/enlargement, leukocyte sludging and/or 
margination [macrophages, eosinophils, neutrophils, and lymphocytes (e.g. NK cells)] within dilated 
capillaries/microvasculature, and edema followed, in severe cases, by microvascular disruption and interstitial 
hemorrhage (1, 3, 12-17, 19, 122, 123).    Persistent and/or recurrent AMR in kidney allografts eventually leads to 
lamination of capillary basement membranes, and capillary rarefaction and loss and replacement fibrosis in both kidney 
and heart allografts(12, 13, 15-17, 122, 124). 
ABO-incompatible liver allografts:  Post-reperfusion biopsies of ABO-incompatible grafts in recipients with high 
pre- titer (>1:32) isoagglutinins, usually show sinusoidal and portal vein platelet-fibrin thrombi, clustering of 
neutrophils, and red blood cell sludging in the sinusoids. These changes are often accompanied by focal hemorrhage into 
the space of Disse and portal connective tissue, focal hepatocellular cytoaggregation, or single cell acidophilic 
necrosis(60).  Follow-up biopsies within the first week in those at risk of developing   acute   AMR   (50%   of   
recipients   that   develop   high   titer   (>1:64) isoagglutinins(105)) after transplantation show portal microvascular 
endothelial cell enlargement/hypertrophy, focal fibrin deposition, portal edema, small, often periportal, hepatocyte 
clusters with coagulative necrosis, and increased red cell congestion and hemorrhage(60, 105).  Other portal tract 
changes include variable fibrinoid degeneration of small portal artery branches, mild usually neutrophilic inflammation, 
focal cholangitis/cholangiolitis, and an interface ductular reaction(60, 105). Portal microvascular (portal veins and 
capillary) endothelia C4d deposition occurs(125), often accompanied by portal stromal C4d, which is reportedly 
characteristic of acute ABO-I AMR, during the first several weeks(106). 
In untreated recipients with high titers, progressive patchy geographic hemorrhagic infarction of the organ ensues 
and those who survive the initial episode can later develop biliary strictures caused by ischemic cholangiopathy (20, 
126, 127).   In recipients harboring low-titer isoagglutinins, endothelial cell C4d positivity in ABO-incompatible grafts 
does not necessarily correlate with other features of acute AMR (128). 
ABO-compatible allografts:  Post-reperfusion biopsies from highly sensitized (high titer/high MFI, often multiple, 
anti-HLA antibodies) ABO-compatible allografts often show platelet aggregates in portal and/or central veins (107, 
129), which can be accompanied by diffuse portal microvasculature C4d staining (113, 115).   Portal microvascular 
endothelial hypertrophy and cytoplasmic eosinophilia, occasionally resulting in “hobnailing”, often appear within 
days to weeks after OLTx in those who develop acute AMR early after transplantation(107, 115, 116).  Other 
features include microvascular dilatation and sludging and/or margination consisting of macrophages, eosinophils, 
lymphocytes, and neutrophils and involving portal vein branches, inlet venules, portal capillaries, peribiliary 
plexus capillaries, occasionally extending into the sinusoids and central veins (Figures 2 and 3). 
The microvascular pathology, described above, is usually accompanied by a variable ductular reaction, 
portal/periportal edema, spotty acidophilic necrosis of hepatocytes, centrilobular hepatocellular swelling and 
hepatocanalicular cholestasis(107, 
115, 116, 130); focal bile duct necrosis; and arterial changes strongly suggestive of arterial vasospasm(107).  
Superimposed TCMR is also very common (107, 115, 116, 
131-133).  When mixed AMR and TCMR exist standard criteria should be used to grade each component and a 
diagnosis of mixed AMR and TCMR should be rendered. Significant AMR can eventually lead to biliary stricture 
development(107, 134, 135), as in ABO-I grafts.   Portal and central sclerotic venous lesions, similar to veno-
occlusive disease, can develop and persist chronically, as discussed below in chronic AMR. Component lesion scoring 
for acute liver AMR are shown in Table  4 and criteria for the diagnosis of acute liver allograft AMR are shown in 
Table 5.  Inflammatory (lymphocytic intimal inflammation)/necrotizing arteritis is rare, but should be considered 
diagnostic of acute AMR when seen in conjunction with diffuse C4d deposits and DSA, as in kidney allografts(2). 
Some histopathological changes resemble preservation/reperfusion injury and obstructive cholangiopathy, but 
microvascular dilatation, microvascular endothelial cell enlargement/hypertrophy, and cytoplasmic eosinophilia and 
“microvasculitis”, especially when involving central veins, distinguish acute AMR from these other complications (21, 
76, 115, 116, 136-138).   Regardless, we recommend stringent diagnostic criteria to establish an AMR diagnosis 
with certainty(112, 115, 116, 136, 137, 139, 140) (Table 5). The histopathological manifestations of acute AMR are 
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the same for preformed and de novo DSA formation. However, the latter tends to be less severe or obvious and 
therefore, can be more difficult to recognize >6 months after liver transplantation, in contrast to kidney and heart 
allografts.  Possible explanations for these inter-organ differences include hepatic resistance mechanisms, discussed 
above. 
 
 
CHRONIC ANTIBODY-MEDIATED INJURY 
 
Chronic AMR General Considerations 
 
Antibody characteristics: Late onset acute AMR, and mixed AMR and TCMR have been reported in 
suboptimally immunosuppressed with persistent, often de novo, DSA+ individuals (121).  Putative chronic liver AMR 
occurs primarily in a currently unknown percentage of the ~8 - 15% of liver allograft recipients that keep or develop 
de novo DSA (121, 141) directed at HLA class II, especially DQ antigens (121, 141).  Risk factors for de novo DSA 
include cyclosporine versus tacrolimus use, low levels of immunosuppression, young age, low Model for End-Stage 
Liver Disease (MELD) score (141), and previous transplants (121). Multivariate analyses show that de novo DSA is 
associated with decreased patient and allograft survival (141) and increased fibrosis development(121). IgG3 subclass 
and C1q testing may help facilitate identification of preformed and de novo DSAs associated with the highest risk 
of allograft damage (44, 
142-144).  However, pathophysiologically linking the antibodies to the tissue pathology has been more difficult for 
chronic than acute liver allograft AMR(21, 22).  In addition, it should be noted that not all patients who develop de 
novo DSA, such as operationally tolerant human liver allograft recipients, experience associated tissue pathology 
over a period of up to 7 years (144, 145). 
Similar difficulties have been encountered in studying and diagnosing chronic AMR in renal allografts(146).  
Regardless, more advanced fibrosis and architectural distortion and decreased graft survival data in DSA+ liver 
allograft recipients strongly suggest that antibodies negatively impact the allograft in a subset (22, 34, 109, 142, 143, 
147, 148), but not all(144), persistently DSA+ liver recipients.  Smith and Colvin(146) summarized similar problems 
encountered in kidney transplantation (21, 22):  “Alloantibodies clearly cause acute antibody mediated rejection, and 
all available evidence supports their pathogenic etiology in the development of chronic alloantibody mediated rejection 
(CAMR). But the slow evolution of this disease, the on-going immunosuppression, the variations in titer of 
alloantibodies, and variation in antigenic targets all complicate identifying which dynamic factors are most important 
clinically and pathologically.” 
An expert renal allograft pathology panel(149) offered the following evidence supporting a pathogenic role 
for antibodies in chronic kidney injury: 1) experimental models of non-human primate renal allografts without 
immunosuppression progress to chronic graft injury and loss through four stages: alloantibody production, peritubular 
capillaries and glomeruli C4d deposition, chronic histopathological changes, and graft loss. 2) large prospective 
studies show circulating anti-HLA antibodies are associated with late graft failure. 3) Histological changes associated 
with late graft loss are found in close association with C4d deposition in peritubular capillaries and presence of anti-
HLA antibodies. Criteria proposed in 2007 to diagnose chronic kidney allograft AMR included:1) histological evidence 
of chronic injury; 2) immunopathological evidence of antibody- mediated graft injury (C4d deposition); and 3) serum 
DSA(150). 
Experts also agree that there is no clear-cut definition of what is meant by “chronic” (149).  “For some it simply 
means burned out scar formation. Others use the word in a broader sense, thinking that there are chronic changes 
with some kind of activity so that chronicity still has an ongoing active component (and thus, a potential need for 
treatment)(149)”.  C4d can potentially reflect recent immunological activity within weeks. Factors such as antibody 
class, subclass, titer, antibody avidity, variable target antigen expression, and the extent of resistance (or 
accommodation) likely contribute to whether acute, chronic, or some other manifestation of antibody binding occurs 
in a particular situation(21, 149).”  More research is clearly needed:  the lack of insight into the natural history of 
chronic renal allograft AMR, let alone liver chronic AMR, makes the optimal therapy unknown (21, 149). 
In comparison, liver allografts,: 1) lack large non-human primate data, although recent small animal models 
are emerging(151, 152); 2) prospective analysis of paired serum and biopsies are just now appearing in the 
literature(153); 3) candidate histopathological lesions found in close proximity with C4d deposits, discussed below, 
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have already been described(34, 44, 128, 139, 147, 154-159); and 4) “activity” might be differently defined in kidney 
versus liver allografts. 
A major problem with the diagnosis of chronic AMR in liver allografts, however, is the lack of specific/typical 
clinical or biochemical features. Instead, many of the histopathological features that have been postulated to occur as 
a consequence of chronic AMR have been observed in protocol biopsies from liver allograft recipients (mostly 
pediatric) who appear to be clinically well with good graft function assessed by liver injury tests. 
 
 
 
Chronic AMR Histopathology 
 
Candidate histopathological lesions of chronic liver allograft AMR that have been associated, albeit not 
necessarily causally, are emerging primarily from:  1) long-term follow-up of pediatric liver allograft recipients(34, 
44, 58, 147, 157, 158, 160); 2) suboptimally immunosuppressed recipients(22, 44, 147, 160); 3) immunosuppression 
weaning studies(147, 161, 162); and 4) from centers that conduct protocol simultaneous serum and biopsy 
samplings(22, 115, 116, 163). Pediatric populations are potentially the most informative since most original diseases 
do not recur following transplantation and recognizing changes potentially associated with chronic AMR should be less 
challenging than in adults where original disease recurrence is more common. This is especially true when candidate 
chronic AMR lesions differ substantially from those encountered with otherwise typical TCMR, viral hepatitis, 
vascular or technical biliary complications. 
DSA appearance has been associated with tolerance loss in kidney allografts (164).   De novo DSA often 
develops in pediatric OLTx recipients weaned from immunosuppression(144, 147) and in patients with chronic 
suboptimal immunosuppression(21, 58, 147, 164). Reports of protocol follow-up biopsies in patients after sustained 
lowering or withdrawal of immunosuppression (IS) are limited (5, 10, 165, 
166). As mentioned above, it is clear that not all patients that develop DSA after weaning experience significant liver 
inflammation, TCMR, fibrosis, architectural deterioration, or changes in sinusoidal endothelial (CD34- to CD34+) or 
stellate cell phenotype (SMA– to SMA+) within five years(144).  Nevertheless, some study endpoints consider de 
novo DSA development a failure, regardless of the liver function or histopathology. 
A spectrum of liver allograft injury (low-grade portal, periportal, and perivenular inflammation, non-
inflammatory fibrosis, biliary strictures, nodular regenerative hyperplasia, etc.), and obliterative arteriopathy is 
suspected in chronic AMR(21, 22, 103). Some of these lesions, such as biliary strictures(107, 134, 135) or sclerotic venous 
lesions might be the result of, or superimposed upon, residual damage from acute AMR and/or TCMR, discussed 
above.  Histopathological lesions currently more strongly associated with  persistent  post-transplant  DSA  include  
portal  and  perivenular  mononuclear inflammation with low-grade interface necro-inflammatory activity and 
portal/periportal, sinusoidal and perivenular fibrosis (Table 6). 
 
The above putative chronic AMR lesions have also been associated with microvascular endothelial C4d 
deposition in most, but not all studies, whereas prominent microvascular inflammation appear to be less common than 
in acute liver allograft AMR(21, 34, 50, 76, 103, 128, 147, 148, 167, 168).  This might be related to lower antibody 
production related to gradual apoptosis-mediated deletion of activated B cells via a PD-L1-mediated mechanism(169) 
or to other liver-related adaptive mechanisms. 
Except for obliterative arteriopathy, most of these candidate lesions can also be caused by technical 
complications (5, 10, 55).  Theoretically, DSA might accentuate or worsen the histopathological lesions of co-existent 
disorders, such as recurrent HCV and TCMR, via upregulate allograft microvascular and other cell HLA II (21, 22, 
103).  In addition to low-grade microvascular inflammation and destruction, potential pathogenic mechanisms linking 
DSA to tissue inflammation and fibrosis include non-microvascular antibody-dependent cellular cytotoxicity (ADCC) 
mechanisms, direct phenotypic modulation/activation of liver endothelial cells, stellate cells and portal myofibroblasts, 
and an association with TCMR. Routine histopathological, serological, immunohistochemical, and clinical criteria 
needed to establish a diagnosis of “possible” and “probable” chronic AMR are shown in Table 7.  Similar to acute 
AMR, stringent criteria are proposed to establish a chronic AMR diagnosis to avoid over-diagnosis until the spectrum 
of potential morphological manifestations are more thoroughly appreciated.  When mixed AMR and TCMR exist 
standard criteria should be used to grade each component and a diagnosis of mixed AMR and TCMR should be 
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rendered. 
 
 
 
Specimen Adequacy, C4d Staining Methods and Interpretation 
 
Guidelines for liver biopsy adequacy, as defined by American Association for the Study of Liver Disease 
AASLD(170)/Banff Working Group(5) includes 2 passes with a 16 gauge needle for adequate assessment of fibrosis. 
Short needle biopsies (< 20 mm) are subject to sampling errors and systematic underestimation of fibrosis(171).  
Biopsies containing < 11 portal tracts might not be representative (reviewed in (170)). 
Linear to granular microvascular endothelial cell staining for complement 4d (C4d), which persists for several 
weeks, is accepted as evidence of complement activation within the tissue at the deposition site(15, 149, 172). C4d 
staining has improved the diagnostic accuracy of liver allograft AMR (140, 173), but C4d deposition does not necessarily 
trigger downstream effector mechanisms and tissue damage(14, 146, 149). As with other organ allografts, 
immunofluorescence staining of frozen tissue for C4d is generally considered to  be  more  sensitive  than  
immunoperoxidase  staining  of  formalin-fixed,  paraffin-embedded (FFPE) tissue after antigen retrieval (174-179).  
Most centers rely on mouse and rabbit monoclonal anti-C4d primary antibodies for frozen tissue.  Therefore, if acute 
or chronic AMR is suspected frozen tissue should be saved for immunofluorescence (IF) C4d staining. Various 
combinations of IgG, IgM, C3, and C4 can be diffusely detected in frozen sections along the sinusoids and in peri-hilar 
arteries, portal veins, and the peribiliary plexus in frozen tissue from livers with acute AMR (60, 107, 136), but are 
neither stable nor reliably present (60, 107, 136). 
Unfortunately, most centers rely on FFPE as a reasonable, albeit less sensitive, alternative to IF on frozen 
tissue.  C4d staining techniques on FFPE affect sensitivity: pressure cooker antigen retrieval yields more sensitive 
results, but background can emerge leading to interpretational problems (106, 138, 173, 180-185).  FFPE sections 
are more often stained with rabbit polyclonal and/or rabbit monoclonal anti-C4d antibodies; a cocktail of monoclonal 
and polyclonal antibodies appears to improve sensitivity. 
An unpublished FFPE tissue microarray C4d staining study (D. Neil, personal communication) showed: a) 
several “best” methods use different primary antibodies, with antigen retrieval performed at both high and low pH 
suggesting that there is no single best antibody or pH of antigen retrieval; and b) “best C4d staining methods” in liver 
showed variable staining in kidney and heart AMR.   Therefore, a liver tissue positive control is ideal, but might 
not be available, so kidney or heart tissue is an acceptable substitution. Regardless, each laboratory should validate its 
anti-C4d antibody reactions against positive and negative controls to monitor the effect of fixation times, processing 
techniques, automation and selection of antibodies. 
Normal liver allograft biopsies are usually negative for endothelial cell C4d staining, but background/nonspecific 
C4d labelling can be seen in: arterial elastic lamina; portal and perivenular elastic fibers; necrotic and steatotic 
hepatocytes, and areas of sinusoidal fibrosis. “True” linear to granular endothelial cell staining of portal veins, portal 
capillaries, sinusoids, central veins, and arterial endothelium, lymphoid nodules, and periductal and portal stromal C4d 
staining has been described in native pediatric livers with hepatitis B (HBV) and C (HCV), and AIH(186) and in 
allografts when other insults are thought to be the primary cause of allograft dysfunction (e.g. biliary obstruction(173),   
recurrent HBV(180) or HCV(181), and plasma cell hepatitis (de novo AIH))(50).  However, these deposits are 
reportedly less widespread and intense than those associated with severe TCMR or acute AMR(76, 113, 138, 140, 187, 
188).  Moreover, recipients with non- rejection causes of allograft dysfunction (e.g. recurrent HCV or non-alcoholic 
fatty liver disease (NAFLD)) are not protected from developing DSA and C4d tissue deposition. In fact, DSA and C4d 
deposits might be more common in these circumstances because of induced upregulation of HLA target antigens(21, 
153, 163). 
C4d staining also might vary and reflect target antigen distribution.  For example, portal venous and capillary, 
arterial, and sinusoidal endothelial C4d staining has been significantly associated with complement-dependent 
cytotoxicity (CDC)+ and DSA+ recipients more often than their negative controls(183); in those with isolated 
AMR(136, 
185); and associated with macrophage and plasma cell infiltrates(138), micro- vasculitis(107, 116), and TCMR (106, 
112, 138, 139, 173, 180-185).  In some studies, C4d deposits were directly proportional to Banff TCMR grade, 
suggesting that “severe” episodes actually represent combined TCMR and AMR(106, 138, 173, 180-185).  Portal 
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microvascular (portal veins and capillaries) and sinusoidal endothelial cell C4d staining appears to be most specific 
for acute AMR(115, 116, 128, 136), whereas portal C4d “stromal” staining seems to be more strongly associated 
with ABO-incompatible acute AMR(106), TCMR(183) and CR(139, 167). C4d deposits are often less intense in putative 
chronic AMR in FFPE sections(153), and can occasionally be minimal to absent similar to renal allografts(146, 189, 
190), although the prevalence of this unknown. 
Since HLA class II target antigen expression can potentially affect antibody binding and C4d fixation, the 
pattern of C4d staining can be contextual.  For example, TCMR manifest primarily as central perivenulitis can locally 
upregulate HLA class II leading to preferential C4d deposition in central vein and perivenular sinusoidal endothelium. 
Recommendations for C4d scoring are shown in Table 4. HLA class II staining might also be helpful to delineate DSA 
target antigen distribution. 
In liver allografts, IF can be more difficult to interpret than FFPE staining because of difficulties with 
recognizing the underlying architecture and background/non-specific staining in elastic fibers and collagen bundles. 
True linear sinusoidal C4d endothelial cell staining is more common in frozen samples, but sinusoidal fibrosis can result 
in non- specific uptake that is mistakenly interpreted as “diffuse” sinusoidal labelling. In addition, saving small frozen 
tissue fragments for IF staining is not a component of inflammatory native liver pathology and special arrangements 
have to be made that often add personnel costs.   However, an effort to save even a small portion of frozen tissue 
is encouraged. 
 
 
 
ACUTE AND CHRONIC AMR TREATMENT 
ABO-incompatible AMR is best prevented. Isoagglutinin titers are tested pre- transplant and therapy with total 
plasma exchange and usually rituximab with or without other modalities (e.g. intra-venous immunoglobulin (IVIg), 
cyclophosphamide, local infusion therapy and splenectomy) is employed to achieve a pre-transplant titer ≤1:8 (1). 
Following transplantation, isoagglutinin titers should be monitored prospectively and therapy instituted if they increase 
to >1:8 (191). 
ABO-compatible AMR therapy has been limited to acute AMR in single center retrospective case reports 
[1-9 patients per report; reviewed(192)]. Further limiting features include the prior lack of severity differentiation, the 
variation in timing of diagnosis relative to onset of disease, variable treatment algorithms, short-term biochemical follow- 
up usually devoid of liver pathology, absence of long-term follow-up, and inevitable publication bias. 
TCMR early after transplant in the presence of preformed DSA and the absence of diagnostic features of acute 
AMR requires the standard approach to TCMR. This occurs more commonly in the presence of preformed class II 
DSA, likely because of Fc biding receptors present on some but not all alloantibodies (86, 193, 194). However, if clear 
features of acute AMR are present before any therapy, or if steroid resistant rejection is diagnosed, one must test for DSA 
in serum, stain for C4d in tissue, and rule out other causes of similar injury to determine the patient fulfills the 
diagnostic criteria for acute AMR (Table 5). The literature is devoid of cases of mild acute AMR, as these likely have 
responded to our standard approach to TCMR with a steroid recycle with or without steroid-resistant rejection therapy 
(195). However, those with moderate to severe AMR necessitate early intervention usually with plasmapheresis and 
IVIg with or without B-cell directed therapy depending on the severity and timing post-transplant of AMR and 
stability of the patient(130, 131, 133, 196-201). 
Given the infrequency of acute AMR, the most important therapeutic target will inevitably be chronic AMR, 
although no published studies exist to date in this area. Drawing from chronic rejection, it is clear that compliance with 
a tacrolimus (as opposed to cyclosporine) based immunosuppression regimen is critical to prevention (in the first year 
after transplant) and possibly treatment (202). However, treatment of both acute and chronic AMR must commence in 
prospective multicenter studies, utilizing strict diagnostic criteria and unified protocols (192)that include severity 
grading, although prevention is always preferable(202). 
 
 
 
BIOPSY FINDINGS IN IMMUNOSUPPRESSION MANAGEMENT 
 
Some pre-weaning biopsy findings associated with unsuccessful immunosuppression weaning, such as 
microvascular C4d deposits(145), portal lymphocytic inflammation (145, 203) and more lobular CD3+ and CD8+ 
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lymphocytes(203) overlap with histopathological changes linked to chronic AMR.  Indeed, several recent protocol 
biopsy studies from large cohorts of stable long-surviving pediatric(204) and adult(153) liver allograft recipients show 
strong associations between portal and perivenular inflammation with necro-inflammatory activity and fibrosis in 
patients with class II DSA.  Conversely, an absence of co-existent pathology before weaning might contribute to 
allograft stability after weaning even when DSA is present possibly because of less HLA II expression (144, 145, 153). 
European multicenter adult trials(166, 205) failed to show a DSA-related predisposition to rejection after 
weaning or an association between DSA and any particular pattern of injury before or after weaning.  However, these 
studies were limited by: 1) suboptimal DSA evaluation, based on ELISA screening, that might have missed class II 
DSAs; and 2) allowance of HCV fibrosis progression pre- and post-weaning. 
Japanese immunosuppression weaning trials, conducted primarily in pediatric recipients, showed increased 
periportal and perivenular fibrosis after weaning, with or without co-existent lymphocytic inflammation(147, 161, 168), 
which were directly or indirectly attributed to IS minimization(147, 161, 168) and development of HLA class II DSA.  
Endothelial and stromal C4d staining, and CD20+ perivenular infiltrates(147), similar to the iWITH screening biopsies 
cited above(204), were described.  Peribiliary plexus capillary and sinusoidal endothelial cell HLA-DR upregulation 
was spatially linked with nearby inflammation, which was most prominent in patients with co-existent TCMR with or 
without perivenular fibrosis(34).  Re-institution or increasing immunosuppression decreased C4d deposits and 
stabilized or reversed perivenular fibrosis(168).   It is tempting to speculate, therefore, that the lymphocytic portal and 
perivenular inflammation tissue C4d deposits in DSA+ recipients might be related to each other and represent 
subclinical combined chronic AMR/TCMR that manifests biochemically after IS lowering(5, 82). 
Because of the above observations, we recommend that restrictive criteria should met before immunosuppression 
minimization, especially with respect to immunological  “activity” within the biopsy manifest as inflammation with 
tissue damage (see Tables 8 and 9). However, a recent study showed increased portal regulatory T cell infiltrates in 
recipients one and three years after immunosuppression withdrawal; these infiltrates decreased after longer follow-up 
and were not associated with progressive fibrosis(206). Relaxed fibrosis criteria are likely appropriate for patients 
after achieving sustained virological response to HCV therapy, as the major cause of fibrosis has been eliminated. 
 
 
 
FUTURE DIRECTIONS 
 
Acute AMR can and must be reliably recognized early in its course. Routine typing of donor and recipient will 
help facilitate diagnosis of this early rare event and provide baseline data needed for DSA determinations. Retrospective 
typing in cases that develop suspicious injury patterns in post-transplant biopsies can be carried out if donor and 
recipients cells and/or nucleic acids are stored. Protocolized monitoring for DSA may be helpful in standard 
immunosuppression management.  Indeed, work is needed to better define: 1) the timing and types of tissue injury or 
alterations (e.g. portal venopathy, portal capillary destruction, patterns of fibrosis, and sinusoidal endothelial cell as well 
as Kupffer cell and stellate cell phenotypic changes) associated with HLA and other non-HLA antibodies (36, 58, 207); 
2) antibody characteristics (C1q, MFI, titer, IgG subclass, etc.) associated with tissue injury; 3) relative contribution of 
AMR to “mixed” TCMR and AMR episodes and whether different and/or more aggressive immunosuppression therapy 
is needed; 4) cost-effective DSA and tissue screening protocols (including routine C4d staining and possibly other 
immunohistochemistry); 5) incorporation of “molecular signatures”(208) into biopsy analysis, including mRNA, 
miRNA, and other “-omics” that might help uncover molecular mechanisms linking antibody binding to tissue changes 
that can be further pursued, in vitro, and, in vivo; and 6) ultimately how   mechanistically different therapeutic 
interactions affect the different histopathological findings in acute and chronic AMR. 
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Table 1. Typical T CELL-MEDIATED REJECTION 
 
 
Grading Criteria (Global Assessment): 
 
x Indeterminate: Portal and/or perivenular inflammatory infiltrate that is related to an allo-reaction, 
but shows insufficient tissue damage to meet criteria for a diagnosis of mild acute rejection (see 
reference below). 
x Mild: Rejection-type infiltrate in a minority of the triads or perivenular areas, that is generally 
mild, and mostly confined within the portal spaces for portal-based rejection and an absence of 
confluent necrosis/hepatocyte dropout for those presenting with isolated perivenular infiltrates. 
x Moderate: Rejection-type infiltrate, expanding most or all of portal tracts and/or perivenular areas 
with confluent necrosis/hepatocyte dropout limited to a minority of perivenular areas. 
x Severe: As above for moderate, with spillover into periportal areas and/or moderate to severe 
perivenular inflammation that extends into the hepatic parenchyma and is associated with 
perivenular hepatocyte necrosis involving a majority of perivenular areas. 
 
Quantitative Scoring (Rejection Activity Index (RAI)):  
Portal Inflammation: 
1)  Mostly lymphocytic inflammation involving, but not noticeably expanding, a minority of the 
triads. 
2)  Expansion of most or all of the triads, by a mixed infiltrate containing lymphocytes with 
occasional blasts, neutrophils and eosinophils. If eosinophils are conspicuous and accompanied 
by edema and microvascular endothelial cell 
hypertrophy is prominent, acute AMR should be considered. 
3)  Marked expansion of most or all of the triads by a mixed infiltrate containing 
blasts and eosinophils with inflammatory spill over into the periportal parenchyma 
 
Bile Duct Inflammation Damage: 
1)  A minority of the ducts are cuffed and infiltrated by inflammatory cells and show only mild 
reactive changes such as increased nuclear:cytoplasmic ratio of the epithelial cells. 
2)  Most or all of the ducts infiltrated by inflammatory cells. More than an occasional duct shows 
degenerative changes such as nuclear pleomorphism, disordered polarity and cytoplasmic 
vacuolization of the epithelium. 
3)  As above for 2, with most or all of the ducts showing degenerative changes or focal luminal 
disruption 
Venous Endothelial Inflammation: 
1)  Subendothelial lymphocytic infiltration involving some, but not a majority of the portal and/or 
hepatic venules 
2)  Subendothelial infiltration involving most or all of the portal and/or hepatic venules with/out 
confluent hepatocyte necrosis/dropout involving a minority of perivenular regions. 
3)  As above for 2, with moderate or severe perivenular inflammation that extends into the 
perivenular parenchyma and is associated with perivenular hepatocyte necrosis involving a 
majority of perivenular regions. 
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Table 2A.  Typical Chronic Rejection Evaluation 
 
 
 
Structure Early Chronic Rejection (at 
least two findings 
should be present) 
Late Chronic Rejection 
(at least two 
findings should be 
 Small Bile Ducts (<60 
µm) 
Senescence-related changes 
involving a majority of ducts 
(see text); bile duct loss 
<50% of portal tracts 
Loss in >=50% of portal 
tracts; degenerative 
changes in remaining 
bile ducts 
Portal tract hepatic 
arterioles 
Occasional loss involving 
<25% of portal tracts 
Loss involving >25% of 
portal tracts 
Terminal hepatic 
venules 
and zone 3 hepatocytes 
Perivenular mononuclear 
inflammation; lytic zone 3 
necrosis and inflammation; 
and mild perivenular 
fibrosis (see below) 
Variable inflammation; 
focal obliteration; 
moderate to severe 
(bridging) fibrosis 
(see below).* 
Large peri-hilar hepatic 
artery branches 
Intimal inflammation, focal 
foam cell deposition 
without luminal 
 
Luminal narrowing by 
intimal foam cells; 
fibrointimal hyperplasia 
Large perihilar bile ducts Inflammation damage and 
focal foam cell deposition 
Mural fibrosis 
Other So-called "transition" 
hepatitis with spotty 
necrosis of hepatocytes 
Sinusoidal foam cell 
accumulation; 
cholestasis 
*Chronic AMR might be contributing to the development of perivenular fibrosis; C4d 
stains and DSA determinations should be considered. 
 
Suggested Fibrosis Scoring(35): 
 
 
 
 
Table 2B Adapted from Venturi et al(35). 
 
Portal/Periportal: 0 (none) – 3 (portal-to-portal or portal-to-central bridging) 
Subsinusoidal: 0 (none) – 3 (thick; marked and diffuse) 
Perivenular: 0 (none) – 3 (central-to-central or central-to-portal bridging) 
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Table 3. Criteria for the diagnosis of plasma cell-rich TCMR*/** 
 
Must fulfil criteria 1 and 3; criteria 2 is desirable, but not absolutely required: 
1)  Portal and/or perivenular plasma cell-rich (estimated >30%) infiltrates with easily recognizable 
periportal/interface and/or perivenular necro-inflammatory activity usually involving a majority of 
portal tracts and/or central veins.  Most of these cases are graded at least “moderate” with a total 
RAI score ≥ 5 because “V score” is usually “3” because of aggressive perivenular activity, 
whereas “Portal Inflammation” score is usually ≥ 2. 
2)  Lymphocytic cholangitis is usually present and a desirable feature, but not absolutely required 
(inflammatory bile duct damage might be a relatively minor component, but Banff component 
score for bile duct injury is usually ≥ 1). 
3)  Original disease other than autoimmune hepatitis. 
 
*C4d stains are recommended on all biopsies diagnosed as plasma cell-rich rejection; IgG and IgG4 
stains might also be considered to better understand the underlying pathophysiology in some 
recipients. 
** Other contributory, but non-essential features include antibodies to GSTT1 in null recipients of 
GSTT1-positive donor livers and the de novo appearance of donor-specific HLA antibodies 
(DSA). 
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Table 4.  Component lesion scoring for acute AMR: 
 
Component lesion scoring for acute AMR: 
C4d-(immune)-score (formalin-fixed, paraffin-embedded*/**): 
0)  No C4d deposition in portal microvasculature 
1)  Minimal (<10% portal tracts) C4d deposition in > 50% of the circumference of portal 
microvascular endothelia (portal veins and capillaries) 
2)  Focal (10-50% portal tracts) C4d deposition in > 50% of the circumference of portal 
microvascular endothelia (portal veins and capillaries) – usually without extension into periportal 
sinusoids 
3)  Diffuse (>50% portal tracts) C4d deposition in in > 50% of the circumference of portal 
microvascular endothelia (portal veins and capillaries) - often with extension into inlet venules or 
periportal sinusoids 
 
* Formalin-fixed, paraffin-embedded tissues are known to show weaker staining than fresh-
frozen tissues, but interpretation of frozen tissues can be more difficult because of 
background/non-specific staining and poor preservation of morphology. Sinusoidal staining 
should be localized to sinusoidal endothelial cells; false positive staining of connective tissue 
fibers can occur in livers with subsinusoidal fibrosis. 
** Ideally the C4d positive control should be a liver allograft, but peritubular capillary 
staining of a kidney allograft is an acceptable alternative h-(histopathology)-score*/**/# 
 
1)  portal microvascular endothelial cell enlargement (portal veins, capillaries, inlet venules) involving 
a majority of portal tracts with sparse microvasculitis defined as 3 – 4 marginated and/or intra-
luminal monocytes, neutrophils, or eosinophils in the maximally involved capillary with generally 
mild dilation (Figure 1). 
2)  monocytic, eosinophilic or neutrophilic micro-vasculitis/capillaritis, defined at least 5 – 10 
leukocytes marginated and/or intra-luminal in the maximally involved capillary prominent portal 
and/or sinusoidal microvascular endothelial cell enlargement involving a majority of portal tracts or 
sinusoids, with variable, but noticeable portal capillary and inlet venule dilatation and variable 
portal edema (Figure 2). 
3)  As above, with marked capillary dilatation, marked microvascular inflammation (10 or more 
marginated and/or intra-luminal leukocytes in the most severely affected vessels) at least focal 
microvascular disruption with fibrin deposition, and extravasation of red blood cells into the portal 
stroma and/or space of Disse (subsinusoidal space) (Figure 3). 
 
* Special stains that help identify capillaries, such as CD31, CD34, and/or PAS are often needed 
to help identify involved portal-based capillaries. 
**Other features commonly seen, but not necessarily associated with severity include ductular 
reaction and cholestasis. 
# Fibrin deposition and RBC sludging occurs earlier and is more common and prominent in 
ABO-incompatible allografts. 
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Table 5.  Criteria for establishing the diagnosis of acute AMR in liver allografts. 
 
Definite for acute/active* AMR (all four criteria required): 
1.  Histopathological pattern of injury consistent with acute AMR, usually including: 
a.  portal microvascular endothelial cell hypertrophy, portal capillary and inlet venule dilatation, 
monocytic, eosinophilic, and neutrophilic portal microvasculitis, portal edema, ductular reaction; 
cholestasis is usually present, but variable; edema and periportal hepatocyte necrosis are more 
common/prominent in ABO-incompatible allografts(60, 105, 106) variable active lymphocytic 
and/or necrotizing arteritis 
2.  Positive serum DSA 
3.  Diffuse (C4d score = 3) microvascular C4d deposition* on frozen or formalin- fixed, paraffin-
embedded tissue in ABO-compatible tissues or portal stromal C4d deposition in ABO-
incompatible allografts. 
4.  Reasonable exclusion of other insults that might cause a similar pattern of injury 
(see text). Most cases will score (C4d-score: 3 + h-score = 5 or 6; see below). 
 
* optimized C4d staining including positive control is critical for proper evaluation 
 
Suspicious for AMR (both criteria required): 
1)  DSA is positive (see definitions). 
Non zero h score with: C4d-score + h-score of 3 or 4. 
Indeterminate for AMR (requires 1 + 2 and 3 or 4): 
1)  C4d-score + h-score is greater than or equal to 2. 
2)  DSA not available, equivocal, or negative 
3)  C4d staining not available, equivocal, or negative 
4)  Co-existing insult might be contributing to the injury. 
 
* Thrombocytopenia, low serum complement levels, persistence of DSA early after 
transplantation, and elevated liver injury tests are usually present, but might not be prominent in 
mild cases. 
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Table 6. Histopathological Changes with post-transplant DSA and AT1R antibodies. 
 
Study No
. 
Pt
 
Age 
Surv(mo
.) 
Association 
between 
DSA 
  
Histopathological Findings Associated with 
DSA 
Yamada et al(34) 28 Pediatric 
> 12 mo. 
Protocol and 
indication 
↑ Portal and perivenular C4d associated with perivenular 
fibrosis 
↑ Perivenular CD3+, CD20+ cells, and ↑ DR expression 
associated with perivenular fibrosis; DSA not assayed in 
this study. 
Miyagawa- 
Hayashino (147) 
79 Pediatric 
Median 11 
yrs 
Protocol ↑ bridging fibrosis or cirrhosis; fibrosis likely to be perivenular; 
higher frequencies of diffuse/focal endothelial C4d staining; 
mild/ 
indeterminate T cell-mediated rejection; 4 DSA- vs 0 DSA+ 
patients off immunosuppression. 
Ohe et al (58) 81 Pediatric 
Median 
16.3 years 
Protocol LBxs ↑ fibrosis with anti-class II DSA. 
All patients with both high-level DSA-DRB1 and high-level 
anti- Angiotensin II receptor type I (AT1R) Ab showed 
advanced fibrosis. 
C4d staining not conducted 
Del Bello et al 
(121) 
267 Adults 
6 – 220 
mo. 
Indication LBx ↑Fibrosis, NOS 
24% of patients with de novo DSA developed acute AMR: 
lymphocytic portal inflammation, lymphocytic cholangitis, 
PV C4d+, endotheliitis 
Salah (128) 143 Pediatric 
and 
adult 
Generally > 
  
Indication LBxs C4d associated with anti-DR DSA, but not all DSA 
C4d associated with bridging fibrosis 
Iacob et al (148) 174 Adults 
67 mo. 
Protocol: 1 + 3 yrs 
and 
indication 
↑Fibrosis, NOS 
DSA strongly correlated with portal capillary C4d (IPEX) 
Portal capillary C4d (IPEX) positivity significantly associated 
with more frequent and earlier graft failure 
Grabhorn et 
al(157) 
43 Pediatric 
> 5 yrs in 
well 
patients 
Protocol LBxs from 
well patients vs 
indication LBxs 
from 
recipients with 
 
 
DSA present more commonly in recipients with severe chronic 
rejection, but no specific pathological findings attributed 
to chronic AMR. 
C4d staining not conducted 
Wozniak et al(44) 50 Pediatric 
~12 yrs. 
Indication LBXs 
Compared 3 groups: 
1) Non-tolerant 
2) de novo AIH 
3) stable 
DSA associated with late immune activity (T cell-mediated 
rejection, de novo AIH, and chronic rejection) 
C4d staining not conducted 
Markiewicz- 
Kijewska(158) 
33 Pediatric 
99 d – 11 
yrs. 
Indication LBxs Possible association between DSA and liver fibrosis. 
Recognized AMR by diffuse C4d and CD20+ or CD138+ 
predominant infiltrates 
Feng et al(204) 157 Pediatric 
> 4 years 
Protocol Deceased donor and Class II DSA predicted assignment to 
patients with interface activity with/out fibrosis whereas only 
recipient age predicted assignment patients with fibrosis, 
 O’Leary et al (153) 90 Adult 
> 5 yrs 
Protocol ↑ portal inflammation and interface activity 
↑ lobular/perivenular inflammation and typical TCMR 
↑ portal venopathy, portal “collagenization” and 
portal/periportal and sinusoidal fibrosis DSA strongly 
correlated with portal capillary and portal stromal C4d (IPEX) 
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Table 7.  Criteria for chronic active liver allograft AMR. 
 
 
 
Probable chronic active AMR (all four criteria are required): 
1)  Histopathological pattern of injury consistent with chronic AMR: both required: 
a.  Otherwise unexplained and at least mild mononuclear portal and/or perivenular 
inflammation with interface and/or perivenular necro- inflammatory activity (Figures 4 and 
5)*. 
b.  At least moderate portal/periportal, sinusoidal and/or perivenular fibrosis**. 
2)  Recent (for example, measured within 3 months of biopsy)circulating HLA DSA in serum samples; 
3)  At least focal C4d-positive (>10% portal tracts) (Figure 5). 
4)  Reasonable exclusion of other insults that might cause a similar pattern of injury 
(see text). 
 
 
 
Possible chronic active AMR: 
1)  As above, but C4d staining is minimal or absent 
 
* it is difficult, at this time, to determine whether the mononuclear infiltrates are related to AMR (e.g. ADCC with 
capillaritis) or TCMR (mostly T effectors cells) or mixed AMR and TCMR. More research is needed on this topic. 
** CD34 and SMA stains might be considered to study sinusoidal capillarization and stellate cell activation. 
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Table 8.  Baseline or Pre-weaning biopsy findings conducive to MINIMIZATON OF IS* 
 
Compartment Findings 
 
 
Portal inflammation 
and interface 
activity 
Preferably absent, but minimal to focal mild portal 
mononuclear inflammation may be present. Interface 
necro-inflammatory activity is absent or 
equivocal/minimal and, if present, involves a minority of 
portal tracts. 
 
 
 
 
Centrizonal/Perivenul
ar inflammation** 
Current Recommended Criteria: Negative for 
perivenular inflammation 
 
Banff 2012 Criteria: Preferably absent, but minimal/mild 
perivenular mononuclear inflammation around a minority 
of central veins without hepatocyte necrosis without 
endothelitis. 
 
 
Bile duct changes 
Absence of lymphocytic bile duct damage, ductopenia 
and biliary epithelial senescence changes, unless there 
is an alternative, non-immunologic explanation (e.g. 
biliary strictures). 
 
 
 
 
Fibrosis* 
Fibrosis, if present, should be mild overall and not 
more than rare portal-to-portal bridging. Perivenular 
fibrosis should not be more than mild according to Banff 
Criteria.  Patients who achieved sustained virologic 
response to HCV treatment might have more substantial 
fibrosis and architectural distortion. 
 
Arteries 
Negative for isolated “v” lesions (lymphocytic 
arteritis)*** obliterative or foam cell arteriopathy. 
*Excludes patients with underlying AIH, HCV, PBC or PSC (see text). More 
substantial fibrosis and architectural distortion can be tolerated in patients who achieved 
sustained virologic response to HCV treatment.  ** Modified from Banff 
2012 recommendations(5) because of widespread recognition that the lesion 
represents a rejection reaction and has the potential to progress and cause perivenular fibrosis 
after weaning. *** “isolated “v” lesions (lymphocytic arteritis) was added to the Banff 2012 
because of evidence of similar lesions in renal allografts leading to a suboptimal outcome even in 
patients maintained on immunosuppression(209). 
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Table 9. Follow-up biopsy findings suggesting that the patient is unlikely to benefit from 
minimal or absent immunosuppression; proceed only with extreme 
caution (see Figure 2). 
 
Compartment Finding(-s) 
 
 
 
Portal inflammation 
and interface 
activity 
Increased portal inflammation compared to pre- 
weaning biopsy especially when associated with 
histopathologic evidence of focally worsening or 
more prevalent lymphocytic bile duct damage, 
interface hepatitis, or appearance of venous 
endothelitis. 
 
Centrizonal/Perivenul
ar inflammation 
New onset perivenular inflammation compared to pre- 
weaning biopsy associated with necro-inflammatory 
activity. 
 
 
Bile duct changes 
New onset biliary epithelial cell senescence changes 
or ductopenia where sampling problems and/or an 
alternative, non-immunologic explanation (e.g. biliary 
stricture) are reasonably excluded. 
 
 
 
 
 
 
 
 
Fibrosis 
Current Recommended Criteria:: Greater than 1 grade 
increase in fibrosis in any one compartment: (a) 
portal/periportal; (b) peri-sinusoidal; or (c) perivenular 
fibrosis; or new onset bridging fibrosis without an 
alternative explanation (e.g. biliary strictures) that 
involves more than one area and not readily 
explained by a sampling error. 
 
Banff 2012 Criteria: Increase of fibrosis over 
consecutive biopsies (see text) without an alternative 
explanation (e.g. biliary strictures). New onset or 
increase of perivenular fibrosis. 
Arteries Any evidence of foam cell or obliterative arteriopathy. 
*Excludes patients with underlying AIH, HCV, PBC or PSC (see text).  ** modified 
from Banff 2012 recommendations(5) to recognize the need to score liver allograft fibrosis 
according to compartments. 
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Figure Legends 
 
 
 
1.   Composite of early acute AMR with mild portal microvascular endothelial cell enlargement (portal 
veins, capillaries, inlet venules) with sparse microvasculitis (h1 score; see Table 4). A) Low 
magnification H&E overview. The lower right inset is shown at high magnification in “D”.  B) C4d 
stain showing diffuse portal microvascular staining in the portal perbiliary plexus and inlet 
venules. This would score as C4d: “3”.  C)  High magnification of the peribiliary capillary plexus 
showing mild endothelial cell hypertrophy and dilatation and monocyte margination (arrows). D)  
High magnification of inlet venules (IV) showing mild endothelial cell hypertrophy and dilatation 
and monocyte margination (*). The h- score for this area would be 1-2. SV: septal venules 
2.   Composite of moderate acute AMR (h2 score; see Table 4) with: A) mild to moderate portal 
microvascular endothelial cell enlargement (portal veins, capillaries, inlet venules) with: B) diffuse 
C4d positivity and easily recognizable microvascular inflammation (inset). Portal lymphocytic 
inflammation is also seen, which likely represents a component of overlapping TCMR. 
3.   Composite of severe acute AMR (h3 score ; see Table 4) with: A) comparison of severe acute 
AMR in liver (left side) versus kidney (right side) (C4d: red; CD68: black).  Note the capillary 
dilatation in both organs.  B) High magnification of a portal tract showing dilated portal capillaries, 
focal interstitial hemorrhage (arrow), and marginated monocytes/macrophages (*).  Higher 
magnification of the liver area outlined by the square in “A” is shown in “C”; h-score: “3”.  Higher 
magnification of the kidney near the arrow in “A” is shown in “D”.  Note the margination of black-
stained monocytes/macrophages in both organs with acute AMR. E: Diffuse portal 
microvascular endothelial cell positivity. C4d score: “3”. 
4.   Changes commonly associated with chronic AMR include portal and perivenular inflammation. 
The portal tract (PT) and central vein (CV) shown in the right panel are illustrated at higher 
magnification in the left panels. 
5.   A) C4d stain of a long-surviving OLTx recipient with a positive DSA showing portal capillary 
positivity.  B) Trichrome stain highlights the mild to moderate portal/periportal, sinusoidal, and 
perivenular fibrosis. 
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